Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2019 - 2026)

Compass Therapeutics has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $15000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 89.29% year-over-year to $15000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151000.0 (down 73.74% YoY) and the FY2025 annual result came in at $276000.0, down 53.14% from the prior year.
• Depreciation & Amortization (CF) slipped to $15000.0 in Q1 2026 per CMPX's latest filing, from $17000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $220000.0 in Q2 2022 and troughed at $15000.0 in Q1 2026.
• A 5-year average of $138882.4 and a median of $154000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) surged 57.26% in 2022, then tumbled 89.29% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $195000.0 in 2022, then fell by 17.44% to $161000.0 in 2023, then retreated by 13.04% to $140000.0 in 2024, then slumped by 87.86% to $17000.0 in 2025, then dropped by 11.76% to $15000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $15000.0, $17000.0, and $19000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.